Paul Hartley

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Ana Strezova, Javier Díez‐Domingo, Kamal Al Shawafi et al. · Open Forum Infectious Diseases · 2022 · 101 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo et al. · Clinical Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment

Michael Schiff, Shane Saunderson, Irina Mountian et al. · Rheumatology and Therapy · 2017 · 60 citations · Full text

Social Sciences, Clinical Sciences, Chronic Illness Self-management +16

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

Kenneth E. Schmader, Myron J. Levin, Katrijn Grupping et al. · The Journals of Gerontology Series A · 2018 · 34 citations · Full text

Veterinary Medicine, Geriatric Medicine, Pharmacotherapy +17

Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial

Paul Hartley, Yue Shentu, Patricia Betz-Schiff et al. · Drugs & Aging · 2015 · 28 citations

Medicine, Endocrinology, Pharmacotherapy +12